Company / Shareholders' Equity
Vericel Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$354.6M
FY2025
5-year range
$111.1M / $354.6M
FY2021-FY2025
Trend
+21.5%
vs FY2024
Sector context
#116 of 213
Health Care
What the data says
At $355M, Vericel's shareholders' equity ranks #116 of 213 in the Health Care sector. Shareholders' Equity has increased for 6 consecutive years, from $23M in FY2019 to $355M in FY2025.
Based on SEC 10-K filings.
$355M in FY2025 with a 5-year CAGR of +28.2%.
Improved from $226M to $355M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +38.2%
- 5-Year CAGR
- +28.2%
- 10-Year CAGR
- -
Sector benchmark
#116 of 213 in Health CareTop 54% of 213This company $354.6M Sector average $2.5B
▼
-86.1% below sector average
Key checks
Key Insights
- Vericel's shareholders' equity has grown for 6 consecutive years.
- 5-year CAGR of +28.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 21.5% year-over-year.
- Ranks #116 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $354.6M | +21.5% |
| FY2024 | $292.0M | +29.2% |
| FY2023 | $226.0M | +68.3% |
| FY2022 | $134.3M | +20.9% |
| FY2021 | $111.1M | +8.7% |
| FY2020 | $102.2M | +353.6% |
| FY2019 | $22.5M | -8.8% |
| FY2018 | $24.7M | +11.6% |
| FY2017 | $22.1M | -37.9% |
| FY2016 | $35.6M | +815.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026